---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-068992"
form_type: "8-K"
ticker: "NKTR"
cik: "0000906709"
company_name: "NEKTAR THERAPEUTICS"
filed_at: "2022-11-03T23:59:59+00:00"
generated_at: "2026-06-22T11:06:13.712529+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Nektar Therapeutics Q3 2022 net loss narrows to $59M; cash at $546M, runway through mid-2025

## Summary
- Cash and investments at $546.4M at Sep 30, down from $628.2M at Q2 end; cash runway through mid-2025.
- Net loss Q3 $59.0M ($0.31 per share) vs $129.7M ($0.70) year ago; revenue $23.6M (non-cash royalty).
- R&D expense fell to $33.6M from $103.7M due to wind-down of bempegaldesleukin program.
- Restructuring/impairment costs $124.3M year-to-date, including $58.5M non-cash lease/equipment impairment.
- Pipeline: NKTR-358 (w/ Lilly) proof-of-concept in atopic dermatitis; NKTR-255 Phase 2 in large B-cell lymphoma planned.

## SEC filing metadata
- accession: 0001213900-22-068992
- form_type: 8-K
- ticker: NKTR
- cik: 0000906709
- company_name: NEKTAR THERAPEUTICS
- filed_at: 2022-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/906709/000121390022068992/0001213900-22-068992-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/906709/000121390022068992/ea167983-8k_nektarther.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-068992
- JSON: https://secwatch.observer/filing/0001213900-22-068992.json
- Plain text: https://secwatch.observer/filing/0001213900-22-068992.txt

## Key facts
- Earnings Releases
  NEKTAR THERAPEUTICS reported third quarter ended September 30, 2022 results: revenue $23.6 million, net income $59.0 million, EPS $0.31 basic and diluted loss per share.
  - Period: third quarter ended September 30, 2022
  - Revenue: $23.6 million
  - Net income: $59.0 million
  - EPS: $0.31 basic and diluted loss per share
  - Result: reported results
  source text: lay the foundation for continued pipeline progress.” Summary of Financial Results Revenue, which primarily includes non-cash royalty revenue, in the third quarter of 2022 was $23.6 million as compared to $24.9 million in the third quarter of 2021. Revenue for the first nine months of 2022 was $70.0 million as compared to $76.9 million in the first nine months of
  evidence_url: https://www.sec.gov/Archives/edgar/data/906709/000121390022068992/0001213900-22-068992-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.